Cycloheximide (Synonyms: 放线菌酮; Actidione; Naramycin A)

目录号: HY-12320 纯度: 99.82%: Data Sheet SDS COA 产品使用指南
FAQs
技术支持

Cycloheximide (Naramycin A) 是一种抗真菌 (antifungal) 抗生素，发现于 Streptomyces griseus，是真核生物蛋白质合成 (protein synthesis) 的抑制剂，抑制体内蛋白质合成和 RNA 合成的 IC₅₀ 值分别为 532.5 nM 和 2880 nM。Cycloheximide 与真核细胞蛋白质合成过程中核糖体 60S 亚基的 E- 位点结合，阻断 eEF2 介导的核糖体易位过程并阻止新蛋白质的合成。Cycloheximide 可抑制铁死亡 (ferroptosis) 并抑制自噬 (autophagy)。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

CAS No. : 66-81-9

1. 客户无需承担相应的运输费用。

2. 同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

可免费申领三个不同产品的试用装。

3. 试用装只面向终端客户。

规格	价格	是否有货
200 mg	￥600	In-stock
500 mg	￥1200	In-stock
1 g		询价
5 g		询价

or 大包装询价

* Please select Quantity before adding items.

Customer Review

MCE 顾客使用本产品发表的 1031 篇科研文献

Cell Viability Assay

RT-PCR

: Cycloheximide purchased from MCE. Usage Cited in: Cell. 2025 Feb 6;188(3):814-831.e21. [Abstract]; Cycloheximide (10 μM; 12 h) almost completely blocks mouse embryonic development.

: Cycloheximide purchased from MCE. Usage Cited in: Cell. 2024 Apr 25;187(9):2288-2304.e27. [Abstract]; Cycloheximide (0.5 μM) blocks global protein synthesis, including that of ATF4, in SLC6A6-KD CD8⁺ T cells.

: Cycloheximide purchased from MCE. Usage Cited in: Signal Transduct Target Ther. 2024 Mar 8;9(1):63. [Abstract]; WB-based detection of the half-life of β-catenin in CHRNA5 silencing or overexpressing ICC cells treated with CHX (2-12 h).

: Cycloheximide purchased from MCE. Usage Cited in: Circulation. 2024 May 28;149(22):1752-1769. [Abstract]; Western blotting analysis of Runx2 levels in mVSMCs treated with 4-HNE and CHX (100 μg/mL) for up to 12 h (n=9).

: Cycloheximide purchased from MCE. Usage Cited in: Mol Cancer. 2024 Jul 9;23(1):141. [Abstract]; Effect of protein synthesis inhibitor Cycloheximide (20 µM) on c-Myc stability in PFKP-depleted LIU-LSC-1 cells over time. Protein expression of PFKP and c-Myc stability by Western blotting (left) and semi-quantification (right).

: Cycloheximide purchased from MCE. Usage Cited in: Mol Cancer. 2024 Apr 29;23(1):86. [Abstract]; 293 cells transfected with the indicated vectors were treated with CHX (20 µg/mL; 15-120 min) and harvested at the indicated time points prior to Western blotting (left).

: Cycloheximide purchased from MCE. Usage Cited in: Mol Cancer. 2024 Jan 24;23(1):23. [Abstract]; Effect of LINC01852 on the endogenous protein level of SRSF5 in CRC cells treated with CHX (50 µg/mL; 1-8 h).

: Cycloheximide purchased from MCE. Usage Cited in: Nat Cell Biol. 2024 May 7. [Abstract]; HeLa cells were pre-treated for 1 h Cycloheximide (CHX, 10 μg/mL) before 3 h Tg treatment. Representative agarose gel showing RT-PCR analysis of XBP1 mRNA splicing levels.

: Cycloheximide purchased from MCE. Usage Cited in: Nat Cell Biol. 2024 May 7. [Abstract]; Cycloheximide (CHX) (10 μg/mL) could significantly diminish the enrichment of IRE1α along with SG marker proteins in HEK293T cells

: Cycloheximide purchased from MCE. Usage Cited in: Nat Cell Biol. 2024 May 7. [Abstract]; HeLa cells were pre-treated for 1 h Cycloheximide (CHX, 10 μg/mL) before 3 h Tg treatment. Representative confocal IF images of IRE1α clusters (red) and G3BP1-positive SGs (green). Scale bar, 10 μm. Shown also is the quantification of the percentage of cells containing colocalized IRE1α-SG clusters and the IRE1α-SG cluster index.

: Cycloheximide purchased from MCE. Usage Cited in: Nat Cell Biol. 2024 May 7. [Abstract]; HeLa cells were pre-treated for 1 h Cycloheximide (CHX, 10 μg/mL) before 3 h Tg treatment. Representative immunoblot analysis of IRE1α and the indicated SG marker proteins.

: Cycloheximide purchased from MCE. Usage Cited in: Nat Cell Biol. 2024 May 7. [Abstract]; Representative IF images of IRE1α clusters (red) co-localizing with G3BP1 (green) in HeLa cells treated with dimethyl sulfoxide (DMSO) control (Ctrl), Tg (1 μM, 3 h), SA (500 μM, 1 h) or HS (43 °C, 1 h) in the absence or presence of CHX (10 μg/mL) pre-treatment.

: Cycloheximide purchased from MCE. Usage Cited in: Neuro Oncol. 2024 Jan 5;26(1):137-152. [Abstract]; Western Blot (WB) analysis of ADAM22 expression in indicated cells after CHX (20 mg/mL) or CHX (20 mg/mL) + BV02 (5 μM) administration for 0 hour, 6 hours, 12 hours, 24 hours, and 48 hours

: Cycloheximide purchased from MCE. Usage Cited in: Drug Resist Updat. 2024 Jul 22:76:101120. [Abstract]; Cycloheximide (200 μg/mL; 15 min). The half-life of BCL7A mRNA in CHX-treated AML (THP-1 and HL-60) cells was detected using qRT-PCR.

: Cycloheximide purchased from MCE. Usage Cited in: ACS Nano. 2024 Jan 22. [Abstract]; The protein levels of SOX2 in 100 μg/mL of PS-NP-exposed Swan 71 cells treated with CHX (10 μg/mL; 4 h) and MG132 (10 μM; 6 h) or chloroquine (CQ) (15 μM; 6 h).

: Cycloheximide purchased from MCE. Usage Cited in: J Extracell Vesicles. 2024 Jul;13(7):e12468. [Abstract]; Cycloheximide (100 µg/mL; 2-6 h) treatment shows that HEXB knockdown accelerates the degradation of LAMP1 protein in Huh7 and PLC/PRF/5 cells.

: Cycloheximide purchased from MCE. Usage Cited in: Signal Transduct Target Ther. 2023 Mar 15;8(1):107. [Abstract]; Immunoblotting analysis of SMAD4 in A2058 cells with or without the knockdown of SIRT7 pre-treated with CHX (50 μg/mL) for 0 h, 4 h and 8 h.

: Cycloheximide purchased from MCE. Usage Cited in: Cancer Commun (Lond). 2022 Aug 16.; H1048 cells with or without HK2 depletion (C) or overexpression (D) were treated with CHX (100 μg/mL; 2-8 h) for the indicated periods of time. Immunoblotting analyses were performed with the indicated antibodies (left). Quantification of CD133 expression levels relative to tubulin expression levels is shown (right).

: Cycloheximide purchased from MCE. Usage Cited in: Cancer Commun (Lond). 2023 Apr 2. [Abstract]; Stability analysis of YAP1. MCF7 and SKBR3 cells were transfected with NEDD4L overexpression plasmid or siNEDD4L for 48 h, then exposed to CHX (100 µg/mL) for 0, 8, 10, or 12 h. WB analysis of YAP1 expression was then performed.

: Cycloheximide purchased from MCE. Usage Cited in: Cancer Commun (Lond). 2023 Mar 1. [Abstract]; Protein stability assays of A498 and CAKI-1 cells with DBT overexpression or not. Cells were treated with 50 μmol/L cycloheximide (CHX) and harvested at 0, 8, 16, and 24 h.

: Cycloheximide purchased from MCE. Usage Cited in: J Virol. 2022 Nov 21;e0152222. [Abstract]; The Cap protein level decreases gradually in all Cycloheximide (CHX; 100 µg/mL; 3, 6, 9, 12 h)-treated cells but decreases more rapidly in IPO5-silenced cells than in control cells.

: Cycloheximide purchased from MCE. Usage Cited in: Signal Transduct Target Ther. 2020 Dec 26;5(1):298. [Abstract]; Western blot analysis of YBX1 and β-tubulin in HepG2-SR cells transfected with si-NC or si-circRNA-SORE and treated with cycloheximide (CHX) (200 μM).

: Cycloheximide purchased from MCE. Usage Cited in: Cell Metab. 2021 Jan 5;33(1):110-127.e5. [Abstract]; p-Stat1 protein levels at different time points in Nampt KO Hepa1–6 cells (top panel) and NMN-pretreated LLC cells (bottom panel) with CHX (100 μg/mL) treatment upon IFNγ stimulation.

: Cycloheximide purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2019 Feb 26;38(1):101. [Abstract]; FBX022 ubiquitinates p21 via the F-box domain HLF and Hep3B are treated with CHX (10 μM), collected at the indicated time points, and immunoblotted for FBXO22, p21 and GAPDH. Quantification of the p21 levels relative to GAPDH expression is shown.

: Cycloheximide purchased from MCE. Usage Cited in: J Exp Clin Cancer Res. 2019 Feb 15;38(1):83. [Abstract]; Western blot analysis of 97-L and 97-H cells incubated with 100 μM CHX in the absence or presence of JQ1.

: Cycloheximide purchased from MCE. Usage Cited in: Antioxid Redox Signal. 2019 May 20;30(15):1831-1848. [Abstract]; Nrf2 and Keap1 degradation in NIH-3T3 cells when protein synthesis is inhibited by 50 μM Cycloheximide (n=3).

: Cycloheximide purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2019 Feb 12;509(3):797-802. [Abstract]; Western analysis of NEK1 and VHL protein expression in the treatment such as CHX.

: Cycloheximide purchased from MCE. Usage Cited in: J Hematol Oncol. 2018 Feb 23;11(1):26. [Abstract]; Immunoblotting analysis of HOXB13 in MCF-7 cells time-dependently treated with 100 μg/mL Cycloheximide (CHX) after being transiently transfected with the indicated plasmids.

: Cycloheximide purchased from MCE. Usage Cited in: Autophagy. 2018;14(12):2155-2170. [Abstract]; Representative western blots show TP53 expression in untreated and Sunitinib-treated primary colon cancer cells.

: Cycloheximide purchased from MCE. Usage Cited in: EBioMedicine. 2018 Aug;34:243-255. [Abstract]; Protein synthesis is inhibited by Cycloheximide (Cyclo).

: Cycloheximide purchased from MCE. Usage Cited in: Cell Death Dis. 2018 May 3;9(5):519. [Abstract]; MCF-7 cells transfected with pIRES2-EGFP-3Flag/BRD7 or pIRES2-EGFP for 24 h and treated with CoCl₂ (150 μM) for 24 h. Then the cells are incubated with 50 μg/mL Cycloheximide (CHX) for the indicated periods of time (0, 1, 3, 6 h). Lysates are harvested from the cells and analyzed by western blotting.

: Cycloheximide purchased from MCE. Usage Cited in: Cell Death Dis. 2018 May 22;9(6):604. [Abstract]; AGS cells transfected with HA-tagged SQSTM1 plasmid, are treated with 25 μg/mL Cycloheximide (CHX) over a 240-min time period or treated with 100 μg/mL PPI for 48 h in pH 7.4 conditions, and then followed by 25 μg/mL CHX over a 240-min time period.

: Cycloheximide purchased from MCE. Usage Cited in: Cell Death Dis. 2018 Oct 12;9(10):1046. [Abstract]; Cycloheximide (CHX) assay is performed to investigate the effects of CIRBP on HIF-1α protein stability.

: Cycloheximide purchased from MCE. Usage Cited in: Chem Biol Interact. 2018 Mar 1;283:59-74. [Abstract]; The expression levels of apoptosis-associated proteins after treatment with morusin or tumor necrosis factor-alpha (TNF-α)/Cycloheximide (CHX). SKOV-3 cells are incubated with the indicated concentrations of morusin or TNF-α (50 ng/mL)/CHX (50 μM) for 24 h. GAPDH is used as a loading control in western blot analysis.

: Cycloheximide purchased from MCE. Usage Cited in: Chem Biol Interact. 2018 Mar 1;283:59-74. [Abstract]; The expression levels of apoptosis-associated proteins after treatment with morusin or tumor necrosis factor-alpha (TNF-α)/Cycloheximide (CHX). A2780 cells are incubated with the indicated concentrations of morusin or TNF-α (50 ng/mL)/CHX (50 μM) for 24 h. GAPDH is used as a loading control in western blot analysis.

: Cycloheximide purchased from MCE. Usage Cited in: J Virol. 2018 Apr 27;92(10). pii: e00238-18. [Abstract]; (A) PK15 cells are transfected with Flag-ORF4 for 24 h, and then treated with CHX for 0, 3, 6, 9, 12, and 15 h respectively. (B) PK15 cells are transfected with Flag-ORF4 for 24 h, and then exposed to both CHX and MG132 for 9h.

: Cycloheximide purchased from MCE. Usage Cited in: Virology. 2019 Apr;530:51-58. [Abstract]; A549 cells are mock infected or infected with H1N1 at an MOI of 1. At 22 h p.i., cells are treated with DMOG for 2 h and then exposed to 50 μg/mL CHX. Cells are harvested at indicated time points after CHX addition and HIF-1α levels were measured by western blotting.

: Cycloheximide purchased from MCE. Usage Cited in: Oncol Lett. 2018 Nov;16(5):5900-5906. [Abstract]; pVHL interacts with NEK8 and promotes NEK8 degradation through the proteasome ubiquitination signaling pathway.

: Cycloheximide purchased from MCE. Usage Cited in: Oncotarget. 2018 Jan 4;9(20):15239-15251. [Abstract]; Protein biosynthesis in MCF-7 cells is blocked with 100 μg/mL of Cycloheximide (CHX). MRTF-A protein levels in cells with or without LiCl co-treatment are measured with Western-blot at different time points.

: Cycloheximide purchased from MCE. Usage Cited in: Oncotarget. 2018 Jan 4;9(20):15239-15251. [Abstract]; Protein biosynthesis in MCF-7 cells is blocked with 100 μg/mL of Cycloheximide (CHX). MRTF-A protein levels in cells with or without LiCl co-treatment are measured with Western-blot at different time points.

: Cycloheximide purchased from MCE. Usage Cited in: Cell Death Dis. 2017 Sep 14;8(9):e3048. [Abstract]; Cells are treated with CHX in the presence or absence of CQ and results show that the decrease NDRG1 observed after CHX treatment is partially recovered upon co-treatment with CHX and CQ.

: Cycloheximide purchased from MCE. Usage Cited in: Biochem Biophys Res Commun. 2017 Sep 2;490(4):1168-1175. [Abstract]; SR-B1 protein is degraded by proteasome pathway. (A) SR-B1 is degraded in a CHX dose-dependent manner in CHO-K1 cells. (B) Time course of SR-B1 degradation in CHO-K1 cells treated with CHX.

: Cycloheximide purchased from MCE. Usage Cited in: Oncotarget. 2016 May 10;7(19):27176-84. [Abstract]; PIG3 silencing does not affect the degradation of HIF-1α protein under hypoxia. Forty-eight hours after transfection with PIG3-siRNA or negative control siRNA, CAKI cells are pretreated under hypoxia for 4 h followed by treatment with 100 μg/mL Cycloheximide (CHX) to block protein synthesis for the indicated times. The mean values from two experiments are connected by the lines. Protein levels are analyzed by Immunoblotting, GAPDH is employed a loading control. All the experiments above are cond

Cycloheximide 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

查看所有亚型

Aminoglycoside Glycopeptide Lipopeptide Macrolide Oxazolidinone Quinolone Tetracycline β-lactam

生物活性
纯度 & 产品资料
参考文献

生物活性

Cycloheximide (Naramycin A), an antifungal antibiotic found in Streptomyces griseus, is an eukaryote protein synthesis inhibitor, with IC₅₀ values of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively. Cycloheximide binds to the E-site of the 60S subunit of the ribosome during the protein synthesis process in eukaryotic cells, blocking the ribosome translocation process mediated by eEF2 and preventing the synthesis of new proteins. Cycloheximide suppresses ferroptosis and inhibits autophagy. Cycloheximide is promising for research of cancer and neuro-related diseases^[1]^[2]^[3]^[4]^[5]^[6]^[7]^[8].

IC₅₀ & Target

IC50: 532.5 nM (protein synthesis), 2.88 μM (RNA synthesis)^[1]

细胞效力
(Cellular Effect)

Cell Line	Type	Value	Description	References
A549	IC₅₀	0.67 μM Compound: 3	Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human A549 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36693198]
AGS	IC₅₀	3.6 μM Compound: Cycloheximide	Cytotoxicity against human AGS cells after 48 hrs by MTT assay Cytotoxicity against human AGS cells after 48 hrs by MTT assay	[PMID: 21899268]
Astrocyte	EC₅₀	0.071 μM Compound: 1	Antiproliferative activity against mouse astrocyte cells by MTT assay Antiproliferative activity against mouse astrocyte cells by MTT assay	[PMID: 17417631]
CCRF-CEM	IC₅₀	0.2 μM Compound: Cycloheximide	Cytotoxicity against human CEM cells assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human CEM cells assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 29778528]
COS-1	IC₅₀	128.31 μM Compound: CYC-HEXI	Cytotoxicity against african green monkey COS1 cells after 24 hrs by MTT assay Cytotoxicity against african green monkey COS1 cells after 24 hrs by MTT assay	[PMID: 23202484]
HCT-15	IC₅₀	52.3 μM Compound: CYC-HEXI	Growth inhibition of human HCT15 cells after 24 hrs by MTT assay Growth inhibition of human HCT15 cells after 24 hrs by MTT assay	[PMID: 28011220]
HCT-15	IC₅₀	54.13 μM Compound: CYC-HEXI	Cytotoxicity against human HCT15 cells after 24 hrs by MTT assay Cytotoxicity against human HCT15 cells after 24 hrs by MTT assay	[PMID: 23202484]
HEK-293T	IC₅₀	> 100 μM Compound: CYC-HEXI	Growth inhibition of HEK293T cells after 24 hrs by MTT assay Growth inhibition of HEK293T cells after 24 hrs by MTT assay	[PMID: 28011220]
HeLa	IC₅₀	1 μM Compound: 3	Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human HeLa cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36693198]
HeLa	IC₅₀	2880.1 nM Compound: 1, CHX	Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting Inhibition of transcriptional activity in human HeLa cells assessed as [3H]uridine utilization after 2 hrs by scintillation counting	[PMID: 20118940]
HeLa	IC₅₀	36 nM Compound: 5	Inhibition of hypoxia-induced HIF1 activation in human HeLa cells by luciferase reporter gene assay Inhibition of hypoxia-induced HIF1 activation in human HeLa cells by luciferase reporter gene assay	[PMID: 15974627]
HeLa	IC₅₀	532.5 nM Compound: 1, CHX	Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy Inhibition of protein synthesis in human HeLa cells assessed as [35S]cysteine/methionine utilization after 2 hrs by scintillation spectroscopy	[PMID: 20118940]
HepG2	IC₅₀	55.12 μM Compound: CYC-HEXI	Growth inhibition of human HepG2 cells after 24 hrs by MTT assay Growth inhibition of human HepG2 cells after 24 hrs by MTT assay	[PMID: 28011220]
HepG2	IC₅₀	57.12 μM Compound: CYC-HEXI	Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay Cytotoxicity against human HepG2 cells after 24 hrs by MTT assay	[PMID: 23202484]
HT-29	IC₅₀	12.8 μM Compound: Cycloheximide	Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay Cytotoxicity against human HT-29 cells after 48 hrs by MTT assay	[PMID: 21899268]
Jurkat	IC₅₀	0.93 μM Compound: Cycloheximide	Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours Inhibitory concentration was evaluated on human Jurkat T-cells after their exposure for 48 hours	[PMID: 11052798]
K562	IC₅₀	< 0.39 μg/mL Compound: 1	Cytotoxicity against mouse K-562 leukemic cell line, by means of standard proliferation assay Cytotoxicity against mouse K-562 leukemic cell line, by means of standard proliferation assay	[PMID: 10479292]
L929	IC₅₀	< 0.39 μg/mL Compound: 1	Cytotoxicity against mouse L-929 fibroblast cell line, by means of standard proliferation assay Cytotoxicity against mouse L-929 fibroblast cell line, by means of standard proliferation assay	[PMID: 10479292]
MCF7	IC₅₀	> 100 μM Compound: Cycloheximide	Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay	[PMID: 21899268]
MCF7	IC₅₀	0.53 μM Compound: 3	Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay Cytotoxicity against human MCF7 cells assessed as reduction in cell viability incubated for 48 hrs by CCK-8 assay	[PMID: 36693198]
MDA-MB-231	IC₅₀	1.2 μM Compound: Cycloheximide	Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay Cytotoxicity against human MDA-MB-231 cells after 48 hrs by MTT assay	[PMID: 21899268]
MDA-MB-231	IC₅₀	101 nM Compound: CHX	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat GGCGGC in 5'- UTR containing luciferase reporter gene assay Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat GGCGGC in 5'- UTR containing luciferase reporter gene assay	[PMID: 32470302]
MDA-MB-231	IC₅₀	142 nM Compound: CHX	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CAACAA in 5'- UTR containing luciferase reporter gene assay Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CAACAA in 5'- UTR containing luciferase reporter gene assay	[PMID: 32470302]
MDA-MB-231	IC₅₀	226 nM Compound: CHX	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat AGAGAG in 5'- UTR containing luciferase reporter gene assay Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat AGAGAG in 5'- UTR containing luciferase reporter gene assay	[PMID: 32470302]
MDA-MB-231	IC₅₀	87 nM Compound: CHX	Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CCGCCG in 5'- UTR containing luciferase reporter gene assay Inhibition of eIF4A1 in human MDA-MB-231 cells assessed as inhibition of cellular-translation incubated for 4 hrs by specific tandem sequence motif repeat CCGCCG in 5'- UTR containing luciferase reporter gene assay	[PMID: 32470302]
Medulloblastoma cell	EC₅₀	0.042 μM Compound: 1	Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay Antiproliferative activity against mouse medulloblastoma cells harboring heterozygous ptch1 gene by MTT assay	[PMID: 17417631]
NCI-H522	IC₅₀	60.1 μM Compound: CYC-HEXI	Cytotoxicity against human NCI-H522 cells after 24 hrs by MTT assay Cytotoxicity against human NCI-H522 cells after 24 hrs by MTT assay	[PMID: 23202484]
NCI-H522	IC₅₀	62.1 μM Compound: CYC-HEXI	Growth inhibition of human NCI-H522 cells after 24 hrs by MTT assay Growth inhibition of human NCI-H522 cells after 24 hrs by MTT assay	[PMID: 28011220]
NIH3T3	IC₅₀	0.25 μM Compound: Cycloheximide	Cytotoxicity against mouse 3T3 cells assessed as growth inhibition measured after 48 hrs by MTT assay Cytotoxicity against mouse 3T3 cells assessed as growth inhibition measured after 48 hrs by MTT assay	[PMID: 30677669]
NIH3T3	IC₅₀	0.26 μM Compound: Cycloheximide	Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay	[PMID: 22437110]
NIH3T3	IC₅₀	0.26 μM Compound: cycloheximide	Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay	[PMID: 20356064]
NIH3T3	IC₅₀	0.3 μM Compound: Cycloheximide	Anticancer activity against mouse 3T3 cells measured after 48 hrs by MTT assay Anticancer activity against mouse 3T3 cells measured after 48 hrs by MTT assay	[PMID: 33421712]
NIH3T3	IC₅₀	0.3 μM Compound: Cycloheximide	Cytotoxicity against mouse 3T3 cells by SRB assay Cytotoxicity against mouse 3T3 cells by SRB assay	[PMID: 29247859]
NIH3T3	IC₅₀	0.8 μM Compound: Cycloheximide	Cytotoxicity against mouse 3T3 cells measured after 48 hrs by MTT assay Cytotoxicity against mouse 3T3 cells measured after 48 hrs by MTT assay	[PMID: 31378596]
NIH3T3	IC₅₀	0.912 μM Compound: cycloheximide	Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay Cytotoxicity against mouse 3T3 cells after 72 hrs by MTT assay	[PMID: 18771242]
NIH3T3	IC₅₀	1.1 μM Compound: Cycloheximide	Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay Cytotoxicity against mouse NIH/3T3 cells after 48 hrs by MTT assay	[PMID: 21899268]
PA-1	IC₅₀	40.6 μM Compound: CYC-HEXI	Growth inhibition of human PA1 cells after 24 hrs by MTT assay Growth inhibition of human PA1 cells after 24 hrs by MTT assay	[PMID: 28011220]
PA-1	IC₅₀	40.6 μM Compound: CYC-HEXI	Cytotoxicity against human PA1 cells after 24 hrs by MTT assay Cytotoxicity against human PA1 cells after 24 hrs by MTT assay	[PMID: 23202484]
PBMC	IC₅₀	0.9 μM Compound: Cycloheximide	Cytotoxicity against human PBMC assessed as decrease in cell viability after 5 days by MTT assay Cytotoxicity against human PBMC assessed as decrease in cell viability after 5 days by MTT assay	[PMID: 29778528]
T47D	IC₅₀	65.13 μM Compound: CYC-HEXI	Growth inhibition of human T47D cells after 24 hrs by MTT assay Growth inhibition of human T47D cells after 24 hrs by MTT assay	[PMID: 28011220]
T47D	IC₅₀	65.13 μM Compound: CYC-HEXI	Cytotoxicity against human T47D cells after 24 hrs by MTT assay Cytotoxicity against human T47D cells after 24 hrs by MTT assay	[PMID: 23202484]
Vero	IC₅₀	0.2 μM Compound: Cycloheximide	Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 3 days by MTT assay Cytotoxicity against African green monkey Vero cells assessed as decrease in cell viability after 3 days by MTT assay	[PMID: 29778528]

体外研究
(In Vitro)

Cycloheximide (200µM，2 或 10 分钟) 在体外抑制 eEF2 介导的 tRNA 易位^[1]。
Cycloheximide (35 μM，1 或 4 小时) 抑制兔主动脉平滑肌细胞和 J774A.1 巨噬细胞新生蛋白合成^[4]。
Cycloheximide (0.5-1 μg/mL，1-3 天) 抑制 C6 胶质瘤细胞增殖，诱导细胞周期阻滞在 G1 期和 S 期，促进 C6 胶质瘤细胞分化^[5]。
注意事项:
1. 传代次数、细胞状态、细胞密度都可能会影响实验效果。需要调整细胞状态至较好时开展实验 (HCT 116 贴壁细胞形态较小，密度大时容易聚团，铺细胞尽量均匀)；
2. 不同细胞系对 Cycloheximide 敏感度不同，检测指标可能有差异，建议参考文献，提前做预实验 (摸索药物处理时间、浓度，抗体条件)，确定实验方案合理可行；
3. 药物现配现用，可超声加热助溶，直至溶液澄清透明; 首次实验用不完时需分装冻存 -20℃；
4. 检测指标 MDM2、c-Myc 蛋白出现双条带，可能是发生了翻译后修饰；
a. c-Myc存在多种翻译后修饰 (c-Myc 多个位点存在磷酸化修饰、乙酰化修饰、泛素化修饰、糖基化修饰)，常出现实际检测分子量与预测条带大小不符，或者两条条带现象^[6]。
b. MDM 2 存在多个磷酸化位点，预测分子量为 55 kDa，但由于存在多种异构体和翻译后修饰，以及 p53 激活时对 MDM2 有剪切作用，实测分子量大小为 90 kDa，60 kDa，可能观察到多个条带^[7]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究
(In Vivo)

Cycloheximide (30、60 或 120 mg/kg, 在用 200 μA 电击训练之前注射）对小鼠记忆测试试验的潜伏期有显著影响 (P<0.001)。在盐水对照中，这种电击水平导致测试试验的延迟明显高于训练中的延迟。Cycloheximide (30 mg/kg，注射) 导致测试试验的潜伏期明显高于盐水对照组。接受较高剂量注射 Cycloheximide 的小鼠在测试试验中的潜伏期与盐水组相当，即在这些条件下较高剂量既不增强也不损害记忆，导致倒 U 型剂量反应曲线用于 Cycloheximide 增强记忆^[2]。
Cycloheximide (200 mg/kg, 腹腔注射，KA 给药前 20 分钟) 在 Kainic acid (KA) (HY-N2309) 诱导的小鼠海马原代神经元中抑制细胞外信号调节蛋白激酶 (p-ERK)、c-Jun N-末端激酶 1 (p-JNK1) 和钙/钙调素依赖性蛋白激酶 II (p-CaMK II) 的磷酸化，以及 c-Fos 和 c-Jun 蛋白表达增加^[8]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male ICR mice^[8]
Dosage:	200 mg/kg
Administration:	i.p., 20 min prior to the administration of KA
Result:	Prevented the memory impairment induced by KA in mice.

分子量

281.35

同用名

放线菌酮; Actidione; Naramycin A

Formula

C₁₅H₂₃NO₄

CAS 号

66-81-9

性状

固体

颜色

White to off-white

中文名称

放线菌酮

结构分类

初始来源

微生物

Streptomyces

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

4°C, protect from light

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

溶解性数据

细胞实验：

DMSO 中的溶解度 : ≥ 100 mg/mL (355.43 mM; 吸湿的 DMSO 对产品的溶解度有显著影响，请使用新开封的 DMSO)

Ethanol 中的溶解度 : 50 mg/mL (177.71 mM; 超声助溶)

H₂O 中的溶解度 : 5 mg/mL (17.77 mM; 超声助溶 (<60°C))

* "≥" means soluble, but saturation unknown.

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.5543 mL	17.7715 mL	35.5429 mL
5 mM	0.7109 mL	3.5543 mL	7.1086 mL
10 mM	0.3554 mL	1.7771 mL	3.5543 mL

查看完整储备液配制表

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 1 year; -20°C, 6 months (protect from light)。-80°C储存时，请在1年内使用， -20°C储存时，请在6个月内使用。

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

摩尔计算器
稀释计算器

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

浓度 _(start)

体积 _(start)

浓度 _(final)

体积 _(final)

动物实验：

请根据您的实验动物和给药方式选择适当的溶解方案。

以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：
——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

方案一

请依序添加每种溶剂： 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 5 mg/mL (17.77 mM); 澄清溶液

此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案二

请依序添加每种溶剂： 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 5 mg/mL (17.77 mM); 澄清溶液

此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案三

请依序添加每种溶剂： 10% EtOH 90% Corn Oil
Solubility: ≥ 5 mg/mL (17.77 mM); 澄清溶液

此方案可获得 ≥ 5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 50.0 mg/mL 的澄清 EtOH 储备液加到 900 μL 玉米油中，混合均匀。
方案四

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (8.89 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；再向上述体系中加入 50 μL Tween-80，混合均匀；然后再继续加入 450 μL 生理盐水定容至 1 mL。
生理盐水的配制：将 0.9 g 氯化钠，溶解于 ddH₂O 并定容至 100 mL，可以得到澄清透明的生理盐水溶液。
方案五

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (8.89 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
2 g SBE-β-CD（磺丁基醚 β-环糊精）粉末定容于 10 mL 的生理盐水中，完全溶解至澄清透明。
方案六

请依序添加每种溶剂： 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (8.89 mM); 澄清溶液

此方案可获得 ≥ 2.5 mg/mL（饱和度未知）的澄清溶液，此方案实验周期在半个月以上的动物实验酌情使用。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

动物溶解方案计算器

请输入动物实验的基本信息：

给药剂量

mg/kg

动物的平均体重

每只动物的给药体积

μL

动物数量

只

由于实验过程有损耗，建议您多配一只动物的量

请输入您的动物体内配方组成：

DMSO +

Tween-80 +

Saline

如果您的动物是免疫缺陷鼠或者体弱鼠，建议 DMSO 中的在最后工作液体系中的占比尽量不超过 2%。

方案所需 助溶剂 包括：DMSO，，均可在 MCE 网站选购。，Tween 80，均可在 MCE 网站选购。

计算结果

工作液所需浓度 : mg/mL

储备液配制方法 : mg 药物溶于 μL DMSO（母液浓度为 mg/mL）。

*In solvent : -80°C, 1 year; -20°C, 6 months (protect from light)

您所需的储备液浓度超过该产品的实测溶解度，以下方案仅供参考，如有需要，请与 MCE 中国技术支持联系。

动物实验体内工作液的配制方法 : 取 μL DMSO 储备液，加入 μL 。 μL ，混合均匀至澄清，再加 μL Tween 80，混合均匀至澄清，再加 μL 生理盐水。

连续给药周期超过半月以上，请谨慎选择该方案。

请确保第一步储备液溶解至澄清状态，从左到右依次添加助溶剂。您可采用超声加热（超声清洗仪，建议频次 20-40 kHz），涡旋吹打等方式辅助溶解。

纯度 & 产品资料

纯度: 99.82%

选择批次：

Data Sheet (683 KB) SDS (644 KB)

COA (287 KB) HNMR (154 KB) LCMS (100 KB)

产品使用指南 (1538 KB)

参考文献

[1]. Schneider-Poetsch T, et al. Inhibition of eukaryotic translation elongation by cycloheximide and lactimidomycin. Nat Chem Biol. 2010 Mar;6(3):209-217. [Content Brief]

[2]. Gold PE, et al. Cycloheximide impairs and enhances memory depending on dose and footshock intensity. Behav Brain Res. 2012 Aug 1;233(2):293-7. [Content Brief]

[3]. Park W S, et al. Therapeutic window for cycloheximide treatment after hypoxic-ischemic brain injury in neonatal rats. J Korean Med Sci. 2006 Jun;21(3):490-4. [Content Brief]

[4]. Croons V, et al. Differential effect of the protein synthesis inhibitors puromycin and cycloheximide on vascular smooth muscle cell viability. J Pharmacol Exp Ther. 2008 Jun;325(3):824-32. [Content Brief]

[5]. Liu X, et al. Induction of cell cycle arrest at G1 and S phases and cAMP-dependent differentiation in C6 glioma by low concentration of cycloheximide. BMC Cancer. 2010 Dec 15;10:684. [Content Brief]

[6]. Maheswaran S, et al. Intracellular association of the protein product of the c-myc oncogene with the TATA-binding protein. Mol Cell Biol. 1994 Feb;14(2):1147-52. [Content Brief]

[7]. Pochampally R, et al. Activation of an MDM2-specific caspase by p53 in the absence of apoptosis. J Biol Chem. 1999 May 21;274(21):15271-7. [Content Brief]

[8]. Lee HK, et al. Cycloheximide inhibits neurotoxic responses induced by kainic acid in mice. Brain Res Bull. 2003 Jun 30;61(1):99-107. [Content Brief]

Cycloheximide 相关分类

完整储备液配制表

可选溶剂	浓度溶剂体积质量	1 mg	5 mg	10 mg	25 mg

H₂O / Ethanol / DMSO	1 mM	3.5543 mL	17.7715 mL	35.5429 mL	88.8573 mL
	5 mM	0.7109 mL	3.5543 mL	7.1086 mL	17.7715 mL
	10 mM	0.3554 mL	1.7771 mL	3.5543 mL	8.8857 mL
	15 mM	0.2370 mL	1.1848 mL	2.3695 mL	5.9238 mL
Ethanol / DMSO	20 mM	0.1777 mL	0.8886 mL	1.7771 mL	4.4429 mL
	25 mM	0.1422 mL	0.7109 mL	1.4217 mL	3.5543 mL
	30 mM	0.1185 mL	0.5924 mL	1.1848 mL	2.9619 mL
	40 mM	0.0889 mL	0.4443 mL	0.8886 mL	2.2214 mL
	50 mM	0.0711 mL	0.3554 mL	0.7109 mL	1.7771 mL
	60 mM	0.0592 mL	0.2962 mL	0.5924 mL	1.4810 mL
	80 mM	0.0444 mL	0.2221 mL	0.4443 mL	1.1107 mL
	100 mM	0.0355 mL	0.1777 mL	0.3554 mL	0.8886 mL

* 备注：如您选择水作为储备液，请稀释至工作液后，再用 0.22 μm 的滤膜过滤除菌后使用。

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Cycloheximide66-81-9Actidione Naramycin A放线菌酮DNA/RNA SynthesisFungalAutophagyFerroptosisAntibioticantibioticeukaryoteproteinsynthesisInhibitorinhibitorinhibit

产品名称：			* 需求量：
* 客户姓名：			* Email：
* 电话：			* 公司或机构名称：
留言给我们：

产品名称：			* Lot #：
* 客户姓名：			* Email：
电话：			* 部门：
* 公司或机构名称：
留言给我们：

MedChemExpress (MCE) 只为有资质的科研机构、医药企业基于科学研究或药证申报的用途提供医药研发服务，不为任何个人或者非科研性质的、非用于药证申报使用等其他用途提供服务。	站点地图隐私声明
沪ICP备15051369号-4 上海工商沪公网安备31011502019417 沪(浦)应急管危经许[2021]201709(QFYS) 营业执照（三证合一）
Copyright © 2013-2025 MedChemExpress. All Rights Reserved.

Cycloheximide (Synonyms: 放线菌酮; Actidione; Naramycin A)

Customer Review

MCE 顾客使用本产品发表的 1031 篇科研文献

Cycloheximide 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

摩尔计算器

稀释计算器

Cycloheximide 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

姓名
邮箱 *

Sorry, but the email address you supplied was invalid.

Cycloheximide (Synonyms: 放线菌酮; Actidione; Naramycin A)

Customer Review

Cycloheximide 相关抗体

MCE 顾客使用本产品发表的 1031 篇科研文献

Cycloheximide 相关产品

•同靶点产品:

•同靶点蛋白产品:

查看 Antibiotic 亚型特异性产品:

生物活性

纯度 & 产品资料

参考文献

Cycloheximide 相关抗体:

摩尔计算器

稀释计算器

Cycloheximide 相关分类

完整储备液配制表

Keywords:

您最近查看的产品:

Request for HNMR Report

Request for HNMR Report

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z